Education and Training
High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma
To assess the role of autologous hematopoietic cell rescue in the treatment of multiple myeloma.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- procedure: high dose chemotherapy then autologous hematopoietic cell transplant
Eligibility
Inclusion Criteria:- received cytoreduction prior to transplant
- adequate organ function Exclusion Criteria:- previous transplant
- smoldering MM or benign monoclonal gammopathy
Ages Eligible for Study
18 Years - 75 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
BMT Referrals
6507230822
Not Recruiting